SCHEMBL2296715

SCHEMBL2296715

CC(O)CC[C@@H](C(=O)O)C(C)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.41
ALDH1A1 P00352 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
GABRR1 P24046 2/20 0.36
CYP1A2 P05177 1/20 0.36
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22205225 1.00 TP53 (0.41) TP53ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL16052820 1.00 TP53 (0.41) TP53ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL22205227 1.00 TP53 (0.41) TP53ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL2296713 1.00 TP53 (0.41) TP53ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL14877096 1.00 TP53 (0.41) TP53ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL9059526 0.92 TP53 (0.47) TP53SLC1A3SLC1A2SLC1A1TDP1
SCHEMBL9650094 0.85 SLC1A3 (0.46) TP53ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL28163012 0.85 SLC1A3 (0.42) TP53SLC1A3SLC1A2SLC1A1TDP1
SCHEMBL28163011 0.85 SLC1A3 (0.42) TP53SLC1A3SLC1A2SLC1A1TDP1
SCHEMBL28163010 0.85 SLC1A3 (0.42) TP53SLC1A3SLC1A2SLC1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108442-A1 COMPOUND FOR USE IN PROTECTING SKIN TDELTAS LTD (GB) 2026-04-23 US claimed
EP-4714505-A2 COMPOUND FOR USE IN PROTECTING SKIN Tdeltas Limited (GB) 2026-03-25 EP claimed
US-11571479-B2 Nutritional composition TDELTAS (GB) 2023-02-07 US claimed
US-20210015730-A1 COMPOUND FOR USE IN PROTECTING SKIN GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF OF HEALTH AND HUMAN SERVICES 2021-01-21 US claimed
US-20200360517-A1 NUTRITIONAL COMPOSITION TDELTAS (GB) 2020-11-19 US claimed
US-10660958-B2 Nutritional composition TDELTAS LIMITED (GB) 2020-05-26 US claimed
EP-2968091-A1 COMPOUND FOR USE IN PROTECTING SKIN Tdeltas Limited (GB) 2016-01-20 EP claimed
WO-2014139599-A1 COMPOUND FOR USE IN PROTECTING SKIN TDELTAS LIMITED (GB) 2014-09-18 WO claimed
US-20130102663-A1 NUTRITIONAL COMPOSITION TDELTAS LIMITED (GB) 2013-04-25 US claimed
EP-2539312-A1 NUTRITIONAL COMPOSITION Tdeltas Limited (GB) 2013-01-02 EP claimed
WO-2011101171-A1 NUTRITIONAL COMPOSITION TDELTAS LIMITED (GB) 2011-08-25 WO claimed
US-20250275986-A1 COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT KETOSWISS AG (CH) 2025-09-04 US disclosed
US-20250008999-A1 Ketone Precursors And Methods Therefor VDF FUTURECEUTICALS, INC. (US) 2025-01-09 US disclosed
CN-118201608-A Ketone precursors and methods thereof VDF未来制剂股份有限公司 2024-06-14 CN disclosed
EP-4373483-A1 COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT KetoSwiss AG (CH) 2024-05-29 EP disclosed
WO-2014071389-A1 KETONE BODIES TO PROTECT TISSUES FROM DAMAGE BY IONIZING RADIATION VEECH RICHARD L (US) 2014-05-08 WO disclosed
WO-2013150153-A1 KETONE BODIES AND KETONE BODY ESTERS FOR MAINTAINING OR IMPROVING MUSCLE POWER OUTPUT TDELTAS LIMITED (GB) 2013-10-10 WO disclosed
US-20130102663-A1 NUTRITIONAL COMPOSITION TDELTAS LIMITED (GB) 2013-04-25 US disclosed
EP-2539312-A1 NUTRITIONAL COMPOSITION Tdeltas Limited (GB) 2013-01-02 EP disclosed
WO-2011101171-A1 NUTRITIONAL COMPOSITION TDELTAS LIMITED (GB) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108442-A1 COMPOUND FOR USE IN PROTECTING SKIN CUTA, POT1, CETP TP53 2897/4885ALDH1A1 1066/4885SLC1A3 317/4885
US-20250275986-A1 COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT PKM, KCNMA1, KCNK18 TP53 4748/4885ALDH1A1 996/4885SLC1A3 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.